Premium Healthcare In Latin America Will Create Future Opportunity

Key Takeaways

• Expansion in specialized healthcare and insurance, coupled with patient retention efforts, is driving improved margins and long-term revenue growth prospects.
  
• Operational efficiencies, risk diversification, and favorable demographic trends are strengthening earnings stability and positioning Auna ahead of industry growth rates.
  
• Operational setbacks, market concentration, economic headwinds, and currency risks threaten Auna's revenue stability, margin performance, and sustainable growth outside its core markets.

Catalysts

A healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia.

• Growth in high-complexity oncology and health insurance offerings through the expansion of OncoSalud in Mexico and increased market share ambitions in Monterrey positions Auna to capitalize on the rising demand for specialized care and premium private healthcare-supporting future revenue and margin expansion.
  
• Patient retention strategies and cross-selling within Auna's vertically integrated ecosystem in Peru are yielding higher conversion of emergency and outpatient visits to higher-tariff surgeries, setting the stage for sustained improvement in patient lifetime value and net margin uplift.
  
• Auna's continued rollout of risk-sharing contracts and payer diversification in Colombia, along with improved collection cycles, are reducing credit risk and supporting a more stable earnings outlook-expected to enhance both top-line and EBITDA resilience in the long run.
  
• Efficiency gains-including ongoing pharmaceutical cost containment and digital platform scaling-are being realized with record-low medical loss ratios in OncoSalud, and are likely to drive further margin improvements and reduce cost pressures across operating regions.
  
• Long-term demographic dynamics (aging populations and growing prevalence of chronic diseases) and increasing middle-class demand for private healthcare in Latin America remain underappreciated tailwinds that are set to drive above-industry-average revenue growth for Auna as it scales its regional hospital and insurance platform.

Auna Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Auna's revenue will grow by 5.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from 1.5% today to 6.1% in 3 years time.
• Analysts expect earnings to reach PEN 329.6 million (and earnings per share of PEN 3.79) by about June 2029, up from PEN 68.7 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as PEN410.0 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 7.4x on those 2029 earnings, down from 15.2x today. This future PE is lower than the current PE for the US Healthcare industry at 23.2x.
• Analysts expect the number of shares outstanding to grow by 0.31% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 10.98%, as per the Simply Wall St company report.

Risks

• Persistent operational setbacks in Mexico-including slow stabilization of physician and supplier relationships, and ongoing disruptions transitioning to Auna's care model-could constrain volume recovery, suppress revenue growth, and press down EBITDA margins if the adjustment process continues to lag.
  
• Strategic risk mitigation in Colombia, such as intentionally slowing growth and selectively managing contracted services to counter payment risk from intervene payers, results in flat top-line growth; if payer instability or reimbursement delays persist, this may create ongoing revenue volatility, cash flow uncertainty, and margin pressure.
  
• Sustained softness and uncertainty in the Mexican economy (notably in the north) due to tariff and trade headwinds could curb private healthcare spending and delay demand rebound, potentially limiting volume-driven revenue growth and constraining overall earnings.
  
• Exposure to significant currency depreciation in Mexico and Colombia-already causing negative impact on as-reported earnings and margins-poses an ongoing risk to reported revenues, EBITDA, and net income, especially as Auna expands in non-Peruvian markets.
  
• High dependence on a concentrated set of markets (Peru, Colombia, and Mexico) and reliance on acquisitions for growth expose Auna to integration risks, adverse regulatory/reimbursement shifts, and increased costs (such as higher compensation to retain top doctors), which may impact net margins, operational efficiency, and sustainable earnings growth over the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $6.99 for Auna based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $5.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be PEN5.4 billion, earnings will come to PEN329.6 million, and it would be trading on a PE ratio of 7.4x, assuming you use a discount rate of 11.0%.
• Given the current share price of $4.15, the analyst price target of $6.99 is 40.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.